145 related articles for article (PubMed ID: 36865499)
1. Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer.
Ye Y; Mo R; Zheng R; Zou J; Liu S; Mi Q; Zhong W
Dis Markers; 2023; 2023():7342882. PubMed ID: 36865499
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
3. A Novel Set of Immune-associated Gene Signature predicts Biochemical Recurrence in Localized Prostate Cancer Patients after Radical Prostatectomy.
Luan JC; Zhang QJ; Zhao K; Zhou X; Yao LY; Zhang TT; Zeng TY; Xia JD; Song NH
J Cancer; 2021; 12(12):3715-3725. PubMed ID: 33995646
[No Abstract] [Full Text] [Related]
4. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
5. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
Ma C; Li F; He Z; Zhao S
Front Surg; 2022; 9():1015263. PubMed ID: 36311939
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel six autophagy-related genes signature for the prognostic and a miRNA-related autophagy predictor for anti-PD-1 therapy responses in prostate cancer.
Wu L; Quan W; Yue G; Luo Q; Peng D; Pan Y; Zhang G
BMC Cancer; 2021 Jan; 21(1):15. PubMed ID: 33402116
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
8. The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.
Liu C; Gao Y; Ni J; Chen S; Hu Q; Wang C; Hu M; Chen M
BMC Cancer; 2022 Jul; 22(1):788. PubMed ID: 35850679
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
10. A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma.
Ma C; Luo H
Clin Res Hepatol Gastroenterol; 2022 Dec; 46(10):102033. PubMed ID: 36265781
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
12. Identification of an EMT-Related Gene Signature for Predicting Overall Survival in Gastric Cancer.
Dai W; Xiao Y; Tang W; Li J; Hong L; Zhang J; Pei M; Lin J; Liu S; Wu X; Xiang L; Wang J
Front Genet; 2021; 12():661306. PubMed ID: 34249086
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
[TBL] [Abstract][Full Text] [Related]
14. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
15. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
17. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma.
Xu Y; Chen Y; Niu Z; Yang Z; Xing J; Yin X; Guo L; Zhang Q; Yang Y; Han Y
Front Surg; 2022; 9():860806. PubMed ID: 35937602
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
Zhang P; Tan X; Zhang D; Gong Q; Zhang X
PLoS One; 2021; 16(5):e0249951. PubMed ID: 33945533
[TBL] [Abstract][Full Text] [Related]
20. Construction and validation of a novel cuproptosis-related long noncoding RNA signature for predicting the outcome of prostate cancer.
Jiang S; Li Z; Dou R; Lin Z; Zhang J; Zhang W; Chen Z; Shen X; Ji J; Qu M; Wang Y; Li M; Gao X
Front Genet; 2022; 13():976850. PubMed ID: 36561322
[No Abstract] [Full Text] [Related]
[Next] [New Search]